Relay Therapeutics, Inc. Common Stock
Here’s whether Relay Therapeutics, Inc. Common Stock (RLAY) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+8.41% over 10 days); RSI 47 — healthy momentum range; strong 1-year return of +401.1%; 3-month momentum positive (+21.9%). Concerns: declining volume on rally — weak conviction (0.55x 30d avg). Currently 11.3% off its 52-week high. Score: +6/7.
RLAY is in a confirmed uptrend, trading above both its 50-day ($16.38) and 200-day ($11.04) moving averages. An RSI of 46.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +401.1% compares to +16.5% for SPY (beat the market by 384.6%).